# Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (MAMBO) Phase I

> **NCT06503848** · — · RECRUITING · sponsor: **Hospital Universitari Vall d'Hebron Research Institute** · enrollment: 108 (estimated)

## Conditions studied

- Migraine Disorders

## Interventions

- **DRUG:** Sumatriptan

## Key facts

- **NCT ID:** NCT06503848
- **Lead sponsor:** Hospital Universitari Vall d'Hebron Research Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-25
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2024-10-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06503848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06503848, "Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (MAMBO) Phase I". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06503848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*